IMGN 779

Drug Profile

IMGN 779

Alternative Names: IMGN779

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; CD33 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Research Myelodysplastic syndromes

Most Recent Events

  • 04 May 2018 IMGN 779 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 09 Dec 2017 Pharmacodynamics and adverse events data from a preclinical study in Acute myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 09 Dec 2017 Interim adverse events, efficacy and pharmacodynamic data from a phase I trial in Acute myeloid leukaemia released by ImmunoGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top